Abstract:Abstract Deubiquitinases (DUBs) play important roles in various human cancers and targeting DUBs is considered as a novel anticancer therapeutic strategy. Overexpression of ubiquitin specific protease 7 and 22 (USP7 and USP22) are associated with malignancy, therapy resistance, and poor prognosis in many cancers. Although both DUBs are involved in the regulation of similar genes and signaling pathways, such as histone H2B monoubiquitination (H2Bub1), c-Myc, FOXP3, and P53, the interdependence of USP22 and USP7 expression has never been described. In the study, we found targeting USP7 via either siRNA-mediated knockdown or pharmaceutical inhibitors dramatically upregulates USP22 in cancer cells. Mechanistically, the elevated USP22 occurs through a transcriptional pathway, possibly due to desuppression of the transcriptional activity of SP1 via promoting its degradation upon USP7 inhibition. Importantly, the elevated USP22 leads to significant activation of downstream signal pathways including H2Bub1 and c-Myc, which may potentially enhance cancer malignancy and counteract the anticancer efficacy of USP7 inhibition. Importantly, targeting USP7 further suppresses the in vitro proliferation of USP22-knockout (USP22-Ko) A549 and H1299 lung cancer cells and induces a stronger activation of P53 tumor suppressor signaling pathway. In addition, USP22-Ko cancer cells are more sensitive to a combination of cisplatin and USP7. USP7 inhibitor treatment further suppresses the in vivo angiogenesis and growth and induced more apoptosis in USP22-Ko cancer xenografts. Taken together, our findings demonstrate that USP7 inhibition can dramatically upregulate USP22 in cancer cells; and targeting USP7 and USP22 may represent a more effective approach for targeted cancer therapy, which warrants further study. Citation Format: Keqiang Zhang, Ting Sun, Wendong Li, Jun Wu, Dan Raz. Inhibition of USP7 upregulates USP22 through desuppression of transcriptional activity of Sp1 in human cancer cells. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3939.

USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1

Ubiquitin-specific peptidase 22 in cancer

Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells

The deubiquitinase USP38 promotes cell proliferation through stabilizing c-Myc

USP2 is an SKP2 Deubiquitylase That Stabilizes Both SKP2 and Its Substrates

USP22 transcriptional activity is negatively regulated by the histone deacetylase inhibitor trichostatin A.

Insights Into the Properties, Biological Functions, and Regulation of USP21

USP11 modulates mitotic progression and senescence by regulating the p53-p21 axis through MDM2 deubiquitination

USP22 promotes development of lung adenocarcinoma through ubiquitination and immunosuppression

USP22 promotes epithelial-mesenchymal transition via the FAK pathway in pancreatic cancer cells

USP10 Regulates p53 Localization and Stability by Deubiquitinating p53

USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination

Deubiquitination and Stabilization of PD-L1 by USP21.

USP22 promotes tumorigenesis and progression by a FKBP12/mTORC1/autophagy positive feedback loop in hepatocellular carcinoma

Deubiquitination of the Repressor E2F6 by USP22 Facilitates AKT Activation and Tumor Growth in Hepatocellular Carcinoma

Supplementary Figures S1-S8 from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

Abstract 3939: Inhibition of USP7 upregulates USP22 through desuppression of transcriptional activity of Sp1 in human cancer cells

USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1

Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms

USP32 deubiquitinase: cellular functions, regulatory mechanisms, and potential as a cancer therapy target

Ubiquitin‐specific Protease 22 Promotes Tumorigenesis and Progression by an FKBP12/mTORC1/autophagy Positive Feedback Loop in Hepatocellular Carcinoma